Last updated Jun 6, 2026
Upsher Smith Labs
Evidence Sources
5
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
1
Confidence Coverage
72%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Immunology
- Corticosteroid
Highest priority development: Upsher Smith's Deflazacort Approval Strengthens Competitive Position in Corticosteroids
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 72%
Active Signals
1
Investigate Priority
0
Opportunity Score
16
Buyer Quality
7 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 6, 2026Score 16FDA Approves Deflazacort Supplement Application by Upsher Smith Labs
Immunology · Corticosteroid
Related Assets
Portfolio asset pages with evidence-based assessments.
- Upsher Smith's Deflazacort Approval Strengthens Competitive Position in CorticosteroidsModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (ORIG)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — DOXYCYCLINE HYCLATE (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — LOSARTAN POTASSIUM (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — DEFLAZACORT (ORIG)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Upsher Smith's Deflazacort Approval Strengthens Competitive Position in CorticosteroidsModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Upsher Smith Labs right now?
- Which regulatory precedents should Upsher Smith Labs monitor in Immunology and Corticosteroid?
- How does Upsher Smith's Deflazacort Approval Strengthens Competitive Position in Corticosteroids compare to the nearest competitive programs?
- What signals require immediate investigation for Upsher Smith Labs?
- Summarize the strategic implications of recent developments for Upsher Smith Labs.
- Where is the greatest uncertainty in Upsher Smith Labs's competitive positioning?